Impact Factor
4.94
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
13.40
10,043 total citations
h5-index
98
h5 depth signal
Cited share
95.8%
768 of 802
Total citations
10,043
Citation footprint
Metric signal
14.83
External metric anchor
Self-citation
0.8%
78 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,001
China
692
United Kingdom
210
Germany
170
Canada
132
Citing Fields of Research
Immunology
789
Oncology
296
Immunotherapy
207
Virology
189
Inflammatory Bowel Diseases & Infections
158
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,298
Articles tracked across the journal lifetime
Indexed publication set
802
768 cited publications
Last 12 months
516
43.0 publications/month
Open access share
99.4%
513 OA publications in the last year
Leading citing country
United States
1,001 citing publications
Leading citing field
Immunology
789 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Apr. 2020-
v1n1, Apr. 2020-
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Broad Categories
Medicine
Immunology
Inflammatory Bowel Diseases & Infections
Lung Cancer
Cancer, Autophagy & Apoptosis
Cancer & Development
Hematology
MeSH Descriptors
Biological Science Disciplines
Biomedical Research
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1016/j.xcrm.2026.103122
Open DOI
20 years of iPSCs: From cellular reprogramming to clinical translation
02
DOI 10.1016/j.xcrm.2026.103103
Open DOI
CD47 fuels intestinal fibrosis by inducing fibroblast phagocytic evasion and represents a therapeutic target
03
DOI 10.1016/j.xcrm.2026.103099
Open DOI
The next click in antibody drug conjugate development
04
DOI 10.1016/j.xcrm.2026.103115
Open DOI
Gut-derived glucagon-like peptides attenuate T cell-induced intestinal injury
05
DOI 10.1016/j.xcrm.2026.103113
Open DOI
Isobavachalcone targets deubiquitinase OTUB1 to induce PD-L1 degradation and enhances antitumor immunity
06
DOI 10.1016/j.xcrm.2026.103117
Open DOI
Targeting oncogenic SOX2 condensates suppresses squamous cell carcinoma progression
07
DOI 10.1016/j.xcrm.2026.103120
Open DOI
Targeting MMGT1 enhances immunotherapy efficacy in triple-negative breast cancer
08
DOI 10.1016/j.xcrm.2026.103116
Open DOI
NKG2D overexpression potentiates CAR-T cells through costimulation by tumor NKG2D ligands
09
DOI 10.1016/j.xcrm.2026.103114
Open DOI
Prediction of immunotherapy response using live tumor fragments from routine clinical biopsies
10
Bibliographical & Catalog Notes
Articles published as they become available and compiled into issues.
Sister journal to: Cell reports.
Complemented by (work): Cell reports 2211-1247 (DLC) 2012247753 (OCoLC)774710944 (DNLM)101573691.